Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - everolimus, quantity: 0.5 mg - tablet, uncoated - excipient ingredients: butylated hydroxytoluene; hypromellose; magnesium stearate; crospovidone; lactose; lactose monohydrate - certican is indicated for the prophylaxis of organ rejection in adult patients at mild to moderate immunological risk receiving an allogeneic renal or cardiac transplant and in adult patients receiving an allogeneic hepatic transplant (see precautions).

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - everolimus, quantity: 0.25 mg - tablet, uncoated - excipient ingredients: butylated hydroxytoluene; lactose monohydrate; hypromellose; magnesium stearate; crospovidone; lactose - certican is indicated for the prophylaxis of organ rejection in adult patients at mild to moderate immunological risk receiving an allogeneic renal or cardiac transplant and in adult patients receiving an allogeneic hepatic transplant (see precautions).

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - carboplatin, quantity: 10 mg/ml - injection, solution - excipient ingredients: water for injections - carboplatin is indicated in the treatment of: advanced stage ovarian cancer of epithelial origin; small cell lung carcinoma; carcinoma of the head and neck; carcinoma of the testis; paediatric cerebral tumours; soft tissue sarcoma; neuroblastoma.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - carboplatin, quantity: 10 mg/ml - injection, solution - excipient ingredients: water for injections - carboplatin is indicated in the treatment of: advanced stage ovarian cancer of epithelial origin; small cell lung carcinoma; carcinoma of the head and neck; carcinoma of the testis; paediatric cerebral tumours; soft tissue sarcoma; neuroblastoma.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - carboplatin, quantity: 10 mg/ml - injection, solution - excipient ingredients: water for injections - carboplatin is indicated in the treatment of: advanced stage ovarian cancer of epithelial origin; small cell lung carcinoma; carcinoma of the head and neck; carcinoma of the testis; paediatric cerebral tumours; soft tissue sarcoma; neuroblastoma.